Research Foundation Calls for Canadian Proposals to Study Chronic Intestinal Disease Therapies Français
The Biocodex Microbiota Foundation is looking for young academics in Canada to help study microbiota and directed therapies to treat intestinal ailments like Crohn's, IBS and celiac's disease.
REDWOOD CITY, Calif., May 10, 2018 /CNW/ -- The Biocodex Microbiota Foundation (BMF), an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is calling for research proposals from innovative researchers at Canadian institutions in the microbiome field.
The Biocodex Microbiota Foundation 2018 Canadian grant will be awarded to a researcher studying microbiota and directed therapies in chronic intestinal diseases. Studies in translational animal models are encouraged, and young academics who are in their first three years of their first appointment or are a senior post-doctoral fellow with a mentor/preceptor for their project are encouraged to apply.
More than 20 million Canadians suffer from digestive disorders every year, according to the Canadian Digestive Health Foundation. These ailments include everything from ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS), and celiac disease. More and more children are particularly vulnerable. In fact, a recent study found that Canada has one of the highest rates of pediatric inflammatory bowel disease in the world, and the number of young children being diagnosed with the lifelong disease has risen sharply. According to the study, conducted by the Canadian Gastro-Intestinal Epidemiology Consortium, estimated 600 to 650 Canadian children are diagnosed with IBS every year, and almost 3,000 children under age 16 are currently living with the disease.
Biocodex, a global pharmaceutical company and maker of the probiotic Florastor®, has been a leading researcher and provider in the microbiota field for the last 60 years. Last year, Biocodex launched in tandem the Biocodex Microbiota Foundation and Biocodex Microbiota Institute, with the goal of uncovering mysteries about the microbiome as it relates to human health and placing reputable data at the fingertips of consumers and healthcare professionals alike.
The Foundation's annual call for projects is part of a multi-year research initiative to understand the interaction between microbiota and different pathologies. By focusing on microbiota and directed therapies in chronic intestinal diseases, the Biocodex Microbiota Foundation aims to understand better ways to help individuals with common gastrointestinal disorders.
The total grant amount is 25,000 euros, and the deadline to submit an application is August 17, 2018. The applications will be reviewed, and the winner chosen by BMF's scientific board, comprised of Dr. Leo Dieleman from University of Alberta, Dr. Elena Verdu from McMaster University, and Dr. Deanna Gibson from University of British Columbia.
More details about the foundation's National Calls for Projects program, application rules and the application are available at the foundation's website. If you have trouble accessing the application, please email [email protected] for a copy of the application.
For more information on the Biocodex Microbiota Foundation, visit http://www.biocodexmicrobiotafoundation.com/foundation.
About Biocodex North America
Biocodex North America is a Silicon Valley-based pharmaceutical company dedicated to providing its customers with meaningful healthcare solutions with an emphasis on gastroenterology and oncology supportive care. Florastor® Daily Probiotic Supplements remain the flagship products, available at all major retailers nationwide. Biocodex North America is a subsidiary of Biocodex, a family-owned multinational pharmaceutical, research, development, manufacturing, and commercial enterprise operating in more than 100 countries. Visit http://www.biocodexusa.com/ or http://www.biocodex.ca/en/ for more information.
About Biocodex Microbiota Foundation
The Biocodex Microbiota Foundation's mission is to support research into microbiota and its interaction with various pathologies. Research is supported through grants given to projects that investigate the implication of microbiota in human health. BMF supports both foundational and applied research, and projects are selected annually by a committee of independent, international scientists.
The BMF's primary activity remains the awarding of annual grants to innovative scientific research projects that explore the structure and impact of microbiota. The BMF also runs and helps establish programs to improve our understanding of microbiota and disseminates this knowledge as widely as possible. Finally, the BMF can establish public projects involving microbiota which aim to help improve human health.
The Biocodex Microbiota Foundation (BMF) is a non-profit, general interest organization.
Contact:
SSPR
Kayli Berlin
[email protected]
(650) 240-6926
SOURCE Biocodex Microbiota Foundation
Share this article